Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026)

Aclaris Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $28.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 5.59% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 5.59% YoY), and the FY2025 full-year result was $20.0 million, down 18.76% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $28.7 million, up from $20.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $68.3 million in Q2 2022, with the low at $20.0 million in Q4 2025.
• Average Cash & Equivalents over 5 years is $36.9 million, with a median of $35.8 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 65.55% in 2022 and plunged 54.37% in 2023.
• Tracing ACRS's Cash & Equivalents over 5 years: stood at $45.3 million in 2022, then dropped by 11.92% to $39.9 million in 2023, then tumbled by 38.39% to $24.6 million in 2024, then fell by 18.76% to $20.0 million in 2025, then surged by 43.59% to $28.7 million in 2026.
• The last three Cash & Equivalents figures came in at $28.7 million (Q1 2026), $20.0 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.

Peer Comparison